BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 235 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.62 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $23,775 | +51.4% | 3,358 | +50.6% | 0.01% | 0.0% |
| Q2 2023 | $15,699 | +51.6% | 2,230 | +79.5% | 0.01% | +66.7% |
| Q1 2023 | $10,358 | -70.2% | 1,242 | -59.0% | 0.00% | -75.0% |
| Q4 2022 | $34,796 | +216.3% | 3,031 | +180.1% | 0.01% | +71.4% |
| Q2 2022 | $11,000 | -15.4% | 1,082 | +31.8% | 0.01% | 0.0% |
| Q1 2022 | $13,000 | +44.4% | 821 | +20.2% | 0.01% | +75.0% |
| Q4 2021 | $9,000 | -10.0% | 683 | -5.1% | 0.00% | -33.3% |
| Q3 2021 | $10,000 | -41.2% | 720 | -32.5% | 0.01% | -45.5% |
| Q2 2021 | $17,000 | +240.0% | 1,066 | +112.8% | 0.01% | +37.5% |
| Q1 2021 | $5,000 | – | 501 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Burrage Capital Management LLC | 864,916 | $13,674,000 | 13.71% |
| Sarissa Capital Management LP | 4,261,000 | $67,366,000 | 5.36% |
| ORACLE INVESTMENT MANAGEMENT INC | 1,920,733 | $30,367,000 | 4.18% |
| HealthCor Management, L.P. | 3,248,100 | $51,352,000 | 2.05% |
| Parkman Healthcare Partners LLC | 351,961 | $5,565,000 | 1.22% |
| Bain Capital Public Equity Management II, LLC | 1,560,730 | $24,675,000 | 1.06% |
| Baker Brothers Advisors | 12,710,818 | $200,958,000 | 0.88% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,835,000 | $44,821,000 | 0.80% |
| Biondo Investment Advisors, LLC | 265,840 | $4,203,000 | 0.72% |
| EAM Global Investors LLC | 157,065 | $2,483,000 | 0.69% |